(Q36395076)

13 August 2017

1 reference

title

Technology Insight: vaccine therapy for prostate cancer (English)

1 reference

13 August 2017

1 reference

Johannes Vieweg

1

1 reference

13 August 2017

Jens Dannull

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 August 2017

Nature Reviews Urology

1 reference

13 August 2017

2

1 reference

13 August 2017

1

1 reference

13 August 2017

44-51

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0079

13 August 2017

0 references

cites work

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Cancer vaccines targeting the HER2/neu oncogenic protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Spinning molecular immunology into successful immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Follow-up evaluation of a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Dendritic cells injected via different routes induce immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Cancer immunotherapy with mRNA-transfected dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

A survey of telomerase activity in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Identification of MUC1 proteolytic cleavage sites in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0079

7 January 2021

Identifiers

DOI

10.1038/NCPURO0079

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference